New Delhi, May 30 (PTI) Sun Pharmaceutical Industries on Tuesday said its new drug application (NDA) of tildrakizumab injection used in the treatment of plaque psoriasis was approved by the Chinese health authority.

The product under the brand name Ilumetri has been approved by China's National Medical Products Administration (NMPA), Sun Pharma said in a statement.

Also Read | RBI To Introduce Expected Loss Approach for Bad Loan Provisioning in 2023-24.

Ilumetri is indicated for the treatment of adults with moderate-to-severe plaque psoriasis, who are candidates for systemic therapy or phototherapy.

In June 2019, the Mumbai-based drug major out-licensed tildrakizumab to a subsidiary of China Medical System Holdings Limited (CMS) for development, regulatory filings and commercialisation of the product in Greater China.

Also Read | Air India Flight Crew Member Assaulted by Passenger: Unruly Flyer Assaults AI Crew Member Onboard Plane, Handed Over to Security at Delhi Airport.

Tildrakizumab Injection has also been approved for marketing in the US, EU, Japan, UK, Switzerland, Canada, Australia, Hong Kong and other countries/regions under the brands of Ilumya and Ilumetri in different geographies.

Psoriasis is a chronic immune disease that appears on the skin. It affects around 125 million people worldwide.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)